Oncohema Key

(1) Mayo Clinic, Jacksonville, Florida, USA   2.1 Introduction Throughout the world diabetic retinopathy (DR) has emerged as a major cause of permanent loss of vision among people over the…

(1) Mayo Clinic, Jacksonville, Florida, USA   3.1 Introduction The lower prevalence of metabolic syndrome throughout the early part of the twentieth century meant that a greater proportion of patients…

(1) Mayo Clinic, Jacksonville, Florida, USA   7.1 Introduction The vitreous humor is the most abundant ocular tissue, comprising the majority (4 ml) of the eye’s volume. Often referred to…

(1) Mayo Clinic, Jacksonville, Florida, USA   4.1 Introduction Laser photocoagulation was the preferred treatment for the complications of diabetic retinopathy – diabetic macular edema (DME) and proliferative diabetic retinopathy…

(1) Mayo Clinic, Jacksonville, Florida, USA   6.1 Introduction The use of the intraocular pharmaceutical agents that were discussed in Chapters 4 and 5 has transformed the treatment of diabetic…

(1) Mayo Clinic, Jacksonville, Florida, USA   5.1 Introduction Drugs that inhibit vascular endothelial growth factor (VEGF) are effective for center-involving diabetic macular edema (DME) since most eyes respond well…

(1) Mayo Clinic, Jacksonville, Florida, USA   1.1 Introduction By 2013, the world’s population reached 7.2 billion with 138.8 million annual births and 54.9 million annual deaths [145]. The global…

(1) Mayo Clinic, Jacksonville, Florida, USA   9.1 Introduction Current pharmacologic treatment of diabetic retinopathy (DR) is based on the intraocular administration of several medications. Injections into the vitreous have…

(1) Mayo Clinic, Jacksonville, Florida, USA   10.1 Introduction Diabetes mellitus (DM) significantly impacts quality of life [8, 16, 48] with affected patients unable to manage their diabetes as well…